

Clinical trials of albiglutide

TrialResults-center www.trialresultscenter.org

1 diabetes type 2

Trial	Treatments	Patients	Trials design and methods
albiglutide vs placebo			
Seino , 2009 [NCT00530309] n=32/8 follow-up: 4 weeks (+5 wk)	albiglutide 15 mg weekly, 30 mg weekly, 50 mg biweekly, and 100 mg monthly versus placebo	Japanese subjects with type 2 diabetes mellitus	Parallel groups single-blind Japan
albiglutide biweekly vs placebo (add on MET)			
Rosenstock (30 mg every two weeks) , 2009 [NCT00518115] n=32/50 follow-up: 16 weeks	albiglutide 30mg weekly versus placebo	patients with type 2 diabetes inadequately controlled with diet and exercise or metformin monotherapy	Parallel groups double blind US, Mexico, Chile, Dominical republic
albiglutide weekly vs placebo (add on MET)			
Rosenstock (30 mg weekly) , 2009 [NCT00518115] n=31/52 follow-up: 16 weeks	albiglutide 30mg weekly versus placebo	patients with type 2 diabetes inadequately controlled with diet and exercise or metformin monotherapy	Parallel groups double-blind US, Mexico, Chile, Dominical republic
albiglutide vs liraglutide			
HARMONY 7 (114179) <i>ongoing</i> [NCT01128894] n=NA follow-up:	weekly albiglutide subcutaneous injection versus liraglutide daily subcutaneous injection, starting at 0.6mg, then up-titrating to 1.2mg then 1.8mg in accordance with prescribing information	subjects with type 2 diabetes	open USA

More details and results :

- insulin secretagogues peptides (incretins) for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q381>
- antidiabetic drugs for diabetes type 2 in patients inadequately controlled on metformin at <http://www.trialresultscenter.org/go-Q509>

- antidiabetic drugs for diabetes type 2 in patients inadequately controlled on monotherapy at <http://www.trialresultscenter.org/go-Q512>

References

Seino, 2009:

Seino Y, Nakajima H, Miyahara H, Kurita T, Bush MA, Yang F, Stewart MW, Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus. *Curr Med Res Opin* 2009;25:3049-57. [19863477] [10.1185/03007990903372999](https://doi.org/10.1185/03007990903372999)

Rosenstock (30 mg every two weeks), 2009:

Rosenstock J, Reusch J, Bush M, Yang F, Stewart M, , Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. *Diabetes Care* 2009;32:1880-6. [19592625] [10.2337/dc09-0366](https://doi.org/10.2337/dc09-0366)

Rosenstock (30 mg weekly), 2009:

Rosenstock J, Reusch J, Bush M, Yang F, Stewart M, , Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. *Diabetes Care* 2009;32:1880-6. [19592625] [10.2337/dc09-0366](https://doi.org/10.2337/dc09-0366)

HARMONY 7 (114179), 0:

ongoing trial NCT01128894

Pratley RE, Nauck MA, Barnett AH, Feinglos MN, Ovalle F, Harman-Boehm I, Ye J, Scott R, Johnson S, Stewart M, Rosenstock J Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. *Lancet Diabetes Endocrinol* 2014;2:289-97 [24703047] [10.1016/S2213-8587\(13\)70214-6](https://doi.org/10.1016/S2213-8587(13)70214-6)

Entry terms: albiglutide,